In silico studies of natural product-like caffeine derivatives as potential MAO-B inhibitors/AA_2AR antagonists for the treatment of Parkinson's disease.

ABSTRACT: Parkinson's disease is considered the second most frequent neurodegenerative disease. It is described by the loss of dopaminergic neurons in the mid-brain. For many decades, L-DOPA has been considered as the gold standard for treating Parkinson's disease motor symptoms, however, due to the decrease of efficacy, in the long run, there is an urgent need for novel antiparkinsonian drugs. Caffeine derivatives have been reported several times for their neuroprotective properties and dual blockade of monoamine oxidase (MAO) and adenosine A_2A receptors (AA_2AR). Natural products are currently attracting more focus due to structural diversity and safety in contrast to synthetic drugs. In the present work, computational studies were conducted on natural product-like caffeine de

SUBMITTER: Boulaamane Y 

PROVIDER: S-EPMC9800045 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature